X

Trial Profile

An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danicopan (Primary)
Indications Membranoproliferative glomerulonephritis
Focus Proof of concept; Therapeutic Use
Sponsors Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease

Most Recent Events

09 Aug 2022 Status changed from completed to discontinued.
07 Mar 2022 Inclusion criteria has been updated to remove the upper age limit of 65 years.
18 Oct 2021 Inclusion criteria has been updated to decrease the lower age limit of subjects from 17 years to 12 years.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com